Alyeska Investment Group
CRVS icon

Alyeska Investment Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Alyeska Investment Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-200,873
Closed -$2.86M – 470
2016
Q2 		$2.86M Buy
200,873
+18,545
+10% +$250K 0.03% 347
2016
Q1 		$2.64M Buy
+182,328
New +$2.62M 0.02% 312

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Alyeska Investment Group's CRVS Position: Q3 2016 in Review

Alyeska Investment Group sold out of Corvus Pharmaceuticals (CRVS) in Q3 2016, closing a stake of 200,873 shares — an estimated $2.86M sold.

Alyeska Investment Group first reported a position in CRVS in Q1 2016 and held it in 2 quarters. The position peaked at $2.86M in Q2 2016. 45 funds tracked by Wall St. Rank hold CRVS as of Q3 2016.

  • Alyeska Investment Group reported no remaining Corvus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Alyeska Investment Group sold 200,873 Corvus Pharmaceuticals shares in Q3 2016, an estimated $2.86M.
  • Alyeska Investment Group first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Alyeska Investment Group's Corvus Pharmaceuticals position peaked at $2.86M in Q2 2016.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2016.

Based on Alyeska Investment Group's 13F filing for Q3 2016, filed 14 Nov 2016.